Earnings Call Summary | Tenon Medical(TNON.US) Q1 2024 Earnings Conference
Earnings Call Summary | Tenon Medical(TNON.US) Q1 2024 Earnings Conference
The following is a summary of the Tenon Medical, Inc. (TNON) Q1 2024 Earnings Call Transcript:
以下是Tenon Medical, Inc.（TNON）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Tenon Medical reported Q1 2024 revenue of $719,000, a 66% increase from the same period last year driven by a 42% rise in surgical procedures utilizing Catamaran system.
Operating losses decreased from $4.9 million in Q1 2023 to $3.5 million in Q1 2024 due to cuts in research and development expenses and third-party sales and marketing expenses.
The company managed to generate $2.6 million from a preferred stock raise in Q1 2024 and retire $1.25 million in secured debt from the previous quarter, ending with no outstanding debt as of March 31, 2024.
Tenon Medical报告称，2024年第一季度收入为71.9万美元，比去年同期增长了66％，这要归因于使用双体船系统的外科手术增长了42％。
由于研发费用以及第三方销售和营销费用削减，营业亏损从2023年第一季度的490万美元减少到2024年第一季度的350万美元。
该公司设法在2024年第一季度通过优先股筹集了260万澳元，并偿还了上一季度的125万美元有担保债务，截至2024年3月31日没有未偿债务。
Business Progress:
业务进展：
Tenon Medical begins its second year of commercialization, with continual advancements and broadening the competitive field with their proprietary Catamaran system.
They are set to increase their marketing, promotion, and workshop efforts as they have conducted more than 500 surgeries with the Catamaran system, showing an exceptional safety profile.
Kristine Jacques has been welcomed to the Board of Directors, and the patent portfolio for the Catamaran system expanded.
Tenon Medical开始了其商业化的第二年，凭借其专有的双体船系统不断进步并扩大了竞争领域。
他们已经使用双体船系统进行了500多次手术，表现出卓越的安全性，因此将加大营销、推广和研讨会的力度。
克里斯汀·雅克受到了董事会的欢迎，双体船系统的专利组合也得到了扩大。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。